Elucidating Therapeutic and Biological Potential of Berberis baluchistanica Ahrendt Bark, Leaf, and Root Extracts
Authors: Gul Zareen , Akbar Ali , Leghari Saadullah Khan 
Published: March 2022

Berberis baluchistanica Ahrendt is a medicinal plant known to have potential for the treatment of various diseases. In the present study, the ethanolic extracts of the bark, leaves, and roots of B. baluchistanica plant were evaluated for in vitro antimicrobial, anti-leishmanial, anticancer, and anti-inflammatory activities. The antibacterial and antifungal activities were determined by agar mix and agar well diffusion method. All extracts showed potential activity against the target bacteria (Bacillus subtilis, Bacillus licheniformis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Rhodococcus erythropolis, Salmonella typhi, and Staphylococcus aureus) and fungal strains (Aspergillus flavus, Aspergillus niger, and Mucor mucedo). S. aureus proved to be the most sensitive strain for each extract, with a maximum zone of inhibition for bark at 23 ± 0.12 mm, for leaves at 22 ± 0.36 mm, and for root extracts at 20.21 ± 0.06 mm). The minimum inhibitory concentration values of B. baluchistanica bark, leaves, and roots for different target bacterial strains ranged from 1.56 to 25 mg ml–1, and the minimum bactericidal concentrations were in the range of 3.12 to 25 mg ml–1, respectively. The root extract possessed potent antifungal activity against A. flavus with 83% of growth inhibition, A. niger with 80%, and M. mucedo with 73%. The bark extract was found active against M. mucedo with 86% of inhibition, followed by 70% against A. flavus and 60% against A. niger. The leaf extract showed a significant response by 83% inhibition against M. mucedo, followed by A. flavus and A. niger with 73 and 72% inhibition, respectively. In an anti-leishmanial bioassay, the inhibitory concentration (IC50) was observed for each extract against Leishmania major. The bark showed good activity (IC50 = 4.95 ± 0.36 mg/ml), followed by the roots (IC50 = 7.07 ± 0.18 mg/ml) and the leaves (IC50 = 8.25 ± 0.29 mg/ml). An evaluation of anticancer activity was done by using MTT cell assay against HeLa cell line. Upon comparing the values of each extract to the standard, it was revealed that the ethanolic bark extract showed the highest anticancer activity with IC50 = (12 ± 0.15 μg/ml), followed by the roots (14 ± 0.15 μg/ml) and the leaves (17 ± 0.21 μg/ml), respectively. The anti-inflammatory assay was undertaken by the inhibition of albumin denaturation activity, proteinase inhibitory activity, and heat-induced hemolysis activity. The IC50 value for protein denaturation of the bark was IC50 = 0.64 ± 0.25 mg/ml, followed by the roots (0.67 ± 0.21 mg/ml) and the leaves (0.73 ± 0.13 mg/ml). The proteinase inhibitory activity of the bark extract was IC50 = 0.55 ± 0.12 mg/ml, followed by the leaves (0.62 ± 0.23 mg/ml) and the roots (0.69 ± 0.15 mg/ml), respectively. For heat-induced hemolysis assay, the bark showed the lowest IC50 value (0.48 ± 0.15 mg/ml) compared to the leaves (0.52 ± 0.35 mg/ml) and the roots (0.58 ± 0.05 mg/ml) of the plant. All analyzed parts of the B. baluchistanica plant showed significant biological activities which make the plant medicinally important and a good candidate for the isolation of antimicrobial, inflammatory, and anticancer compounds. Further studies may lead us to determine the active compounds responsible for the biological activities of the plant extracts.